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ABSTRACT 
The prognostic implications of flow, assessed by stroke volume index (SVi), and left 
ventricular (LV) global longitudinal strain on survival of patients with low gradient severe 
aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF) are debated. The 
aim of this study was to evaluate the impact of flow and LV global longitudinal strain on 
survival of these patients treated with aortic valve replacement (AVR). Low gradient severe 
AS patients with preserved LVEF treated with AVR (N=134, age 76±10 years, 50% men) 
were included in the current study. Aortic valve hemodynamics and LV function were 
assessed with 2-dimensional, Doppler and speckle-tracking echocardiography pre AVR. 
Patients were dichotomized based on low (SVi≤35ml/m2) or normal (SVi>35ml/m2) flow and 
impaired (>-15%) or more preserved (≤-15%) global longitudinal strain. The end-point was 
all-cause mortality. During a median follow-up of 1.8 years (interquartile range 0.5-3 years) 
after AVR, 26 (19.4%) patients died. Survival was better for patients with SVi>35ml/m2 or 
global longitudinal strain ≤-15% as compared with patients with SVi≤35ml/m2 or global 
longitudinal strain >-15% (log-rank p=0.01). Atrial fibrillation (hazard ratio 5.40, 95% 
confidence interval 1.81-16.07, p=0.002) and chronic kidney disease (hazard ratio 3.67, 95% 
confidence interval 1.49-9.06, p=0.005) were the clinical variables independently associated 
with all-cause mortality. The addition of global longitudinal strain (X2 19.87, p=0.029 and C-
statistics 0.74) or SVi (X2 29.62, p<0.001 and C-statistics 0.80) to a baseline model including 
atrial fibrillation and chronic kidney disease (X2 14.52, C-statistics 0.68) improved risk 
stratification of these patients. In conclusion, flow and LV global longitudinal strain are 
independently associated with survival after AVR in low gradient severe AS patients with 
preserved LVEF.  
 
Keywords: Low gradient severe aortic stenosis; Aortic valve replacement; Survival; 
Echocardiography  
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INTRODUCTION 
The decision making of patients with low gradient (mean pressure gradient 
≤40mmHg) severe aortic stenosis (AS) (aortic valve area index, AVAi ≤0.6cm2/m2) with 
preserved left ventricular (LV) ejection fraction (EF) (≥50%) has been source of debate.1, 2 
While some studies have reported better survival of these patients after aortic valve 
replacement (AVR),3, 4 others have suggested that these patients have comparable 
prognosis to that of patients with moderate AS.5 The underlying mechanisms influencing the 
outcome of these patients remain unclear. Despite having preserved LVEF, these patients 
have impaired LV mechanics as assessed with LV global longitudinal strain speckle tracking 
echocardiography and may have normal or low forward flow evaluated by stroke volume 
index (SVi).3, 6 The influence of flow and LV global longitudinal strain on the prognosis of 
patients with preserved LVEF low gradient severe AS remains unexplored. The present 
evaluation assessed the relative merits of flow and LV global longitudinal strain to predict the 
outcome of patients with severe AS, low gradient and preserved LVEF who underwent AVR.  
 
METHODS 
Patients with symptomatic low gradient severe AS and preserved LVEF who 
underwent AVR were identified from an ongoing registry and were included in the current 
analysis (Figure 1).7  
Patients were clinically evaluated and data were collected on a dedicated 
departmental Cardiology Information System (EPD-Vision®, Leiden University Medical 
Center, Leiden, The Netherlands) and analyzed retrospectively. Demographics, clinical 
symptoms (New York Heart Association (NYHA) functional class), cardiovascular risk 
factors, medications and presence of atrial fibrillation, chronic kidney disease (defined as 
moderately to severely decreased creatinine clearance <45ml/min)8 and chronic pulmonary 
obstructive disease were collected. The Institutional Review Board approved this 
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retrospective analysis of clinically acquired data and waived the need for written patient 
informed consent. 
All patients underwent a complete transthoracic echocardiogram using commercially 
available ultrasound systems (Vivid-7 and E9, General Electric, Horten, Norway) equipped 
with 3.5MHz or M5S transducers. Two-dimensional, colour-, pulsed-wave and continuous-
wave Doppler data were acquired in the parasternal and apical views and were stored 
digitally and analyzed offline on a dedicated workstation (EchoPac 112.0.1, GE Medical 
Systems, Horten, Norway). LV dimensions and wall thickness were measured from the 
parasternal long-axis view according to current recommendations.9 LV mass was estimated 
according to the formula by Devereux et al.9 Relative wall thickness and the ratio of LV mass 
to LV end-diastolic volume were calculated as previously described.10 LV end-diastolic and 
end-systolic volumes were measured in the apical 4- and 2-chamber views and indexed to 
body surface area and LVEF was derived using the Simpson’s biplane method.9 SVi was 
estimated by multiplying LV outflow tract area by LV outflow tract velocity time integral on 
pulse-wave Doppler recordings and then indexed to body surface area. Cardiac output was 
calculated as the product of stroke volume and heart rate. Stroke work was calculated by the 
formula (mean arterial pressure + mean peak gradient) x stroke volume x 0.0136 and 
indexed to LV mass.11 Peak and mean pressure transaortic gradients were measured in the 
3- or 5-chamber apical views according to the simplified Bernoulli equation. AVA was 
calculated with the continuity equation and then indexed to body surface area. In addition, 
energy loss index, valvulo-arterial impedance, systemic vascular resistance and systemic 
arterial compliance were calculated as previously described.12 
 For further evaluation of LV systolic function, offline 2-dimensional speckle tracking 
longitudinal strain analysis was performed at a workstation with commercially available 
software (EchoPac 112.0.1, GE Medical Systems, Horten, Norway). From the apical 3-, 4- 
and 2- chamber views, global longitudinal strain was measured and averaged. Transmitral 
pulsed-wave Doppler was used for assessment of LV diastolic function. Additionally, left 
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atrial volume was evaluated according to the biplane area-length method and then indexed 
to body surface area.9 Co-existing valvular dysfunction was assessed based on the 
European Association of Echocardiography and the American Society of Echocardiography 
recommendations.12       
 Based on SVi patients were divided into two categories: low flow was defined as 
SVi≤35ml/m2 and normal flow as SVi>35ml/m2.6, 13, 14 Patients were also categorized as 
having an LV global longitudinal strain ≤-15% or >-15%.7, 15-17 
The end-point of the study was all-cause mortality. All patients were followed-up after 
AVR. Survival data were collected either from the departmental Cardiology Information 
System (EPD-Vision®, Leiden University Medical Center, Leiden, the Netherlands), or by 
telephone interview or by the Social Security death index and were complete for all subjects 
included in the study. 
Categorical variables are expressed as counts (frequency) and continuous variables 
as mean ± standard deviation. Continuous variables were compared between the 2 groups 
(survivors versus non-survivors) with the Student-t test or Mann-Whitney U test, as 
appropriate and categorical variables with the Chi-square test or Fisher exact test, as 
appropriate. The intra- and interobserver reproducibility of LV global longitudinal strain and 
SVi measurements were assessed by the intraclass correlation coefficient. The cumulative 
event rates were calculated based on Kaplan-Meier method and comparisons between 
groups were assessed by log-rank test. Cox proportional hazard ratio regression analyses 
were performed to investigate univariate and multivariate correlates of all-cause mortality. 
Hazard ratios and 95% confidence intervals were reported. Variables with univariate p<0.10 
were entered in the multivariate analysis. The incremental value of flow and LV global 
longitudinal strain category over a baseline clinical model was estimated by the significant 
change in chi-square of the baseline model. The relative fit of each model was calculated 
with the −2 log likelihood. Moreover, C-statistics was used for model comparison. Statistical 
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significance was considered for p value <0.05. Statistical analysis was performed with the 
SPSS software version 20 (SPSS, Chicago, IL).  
 
RESULTS  
The baseline characteristics of 134 patients (75.5±9.9 years old, 50% male) are 
summarized in Table 1. Surgical AVR was performed in 71 (53%) patients and transcatheter 
AVR in the remaining 63 (47%). Echocardiographic data are summarized in Table 2. Low 
flow was identified in 48 (36%) patients and normal flow in 86 (64%) whereas an LV global 
longitudinal strain >-15% was observed in 67 (51%) patients and ≤-15% in 65 (49%). LV 
global longitudinal strain measurement was feasible in 132 (98%) patients. The intraclass 
correlation coefficients for intra and interobserver reprodcubility were 0.95 (95% confidence 
interval 0.69–0.99) and 0.87 (95% confidence interval 0.50-0.97)  for LV global longitudinal 
strain, respectively, and 0.90 (95% confidence interval 0.60-0.97) and 0.88 (95% confidence 
interval 0.55-0.97) for SVi, respectively.  
During a median follow-up of 1.8 years (interquartile range 0.5-3 years) after AVR, 26 
(19.4%) patients died. There were no patients lost at follow-up. At baseline, patients who 
died exhibited more frequently associated co-morbidities (atrial fibrillation, chronic kidney 
disease, chronic pulmonary obstructive disease), previous cardiac surgery and worse NYHA 
functional class as compared with survivors (Table 1). Aortic valve hemodynamics were 
comparable between non-survivors and survivors. However, non-survivors had a higher LV 
global afterload, more concentrically remodelled LV, lower flow and more impaired LV global 
longitudinal strain than survivors (Table 2).  
When dichotomizing the population based on low flow and normal flow, patients with 
low flow had higher mortality rates at 1, 2 and 3 years follow-up after AVR than patients with 
normal flow (16.7%, 25.0% and 33.3% vs. 2.3%, 3.5% and 4.6%, respectively, log-rank 
p<0.001). This difference remained significant after adjusting for age, atrial fibrillation, 
chronic pulmonary obstructive disease, chronic kidney disease, NYHA functional class and 
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LV global longitudinal strain; patients with normal flow had significantly better outcome than 
low flow patients (Figure 2). When dividing the population according to the pre-specified LV 
global longitudinal strain cut-off value, patients with more impaired global longitudinal strain 
(>-15%) had significantly increased mortality at 1, 2 and 3 years after AVR in comparison 
with patients with more preserved global longitudinal strain (≤-15%) (mortality rate 13.4%, 
19.4% and 22.4% vs. 1.5%, 3.1% and 7.7%, respectively, log-rank p=0.01). Survival 
remained significantly higher in the cohort of patients with global longitudinal strain ≤-15% 
after adjusting for age, atrial fibrillation, chronic pulmonary obstructive disease, chronic 
kidney disease, NYHA functional class and SVi (Figure 3). Figure 4 shows the cumulative 
survival for patients grouped according to global longitudinal strain and flow. Patients with a 
global longitudinal strain >-15% and SVi≤35ml/m2 had the worse prognosis. There were 6 
patients who died within 30 days post AVR (50% had TAVR). All of them (100%) had 
impaired global longitudinal strain (>-15%) and 5 (83%) had low-flow. Perioperative mortality 
was significantly higher in the group with more impaired global longitudinal strain (>-15%) 
compared with the group with ≤-15% (log rank p=0.015) and in the low-flow compared to the 
normal-flow group (log rank p=0.014). 
The univariate Cox-regression analysis demonstrated that the presence of atrial 
fibrillation, chronic pulmonary obstructive disease, chronic kidney disease, previous 
myocardial infarction and previous cardiac surgery were associated with increased all-cause 
mortality risk in this population (Table 3). From the echocardiographic variables, lower 
valvulo-arterial impedance and LV mass/LV end-diastolic volume ratio were associated with 
improved survival after AVR. Atrial fibrillation and chronic kidney disease were independently 
associated to mortality after AVR and were selected to build a baseline clinical model to test 
the independent association between flow and global longitudinal strain with survival (Table 
3). Global longitudinal strain >-15% and each 1% impairment in global longitudinal strain 
were independently associated with all-cause mortality (Table 4). In addition, SVi ≤35ml/m2 
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and each 5ml/m2 decrease in SVi were independently associated with all-cause mortality 
(Table 4).  
 
DISCUSSION 
The present evaluation showed that patients with preserved LVEF, low gradient 
severe AS and normal flow or LV global longitudinal strain ≤-15% have better survival after 
AVR compared to their counterparts with low flow or global longitudinal strain >-15%. The 
addition of flow and LV global longitudinal strain to a clinical model improved the risk 
stratification of patients with preserved LVEF, low gradient severe AS treated with AVR.    
Severe aortic stenosis based on AVAi calculation but with low gradient is observed in 
almost 35% of patients with preserved LVEF.4-6, 10, 18, 19 Decision making in this subgroup of 
patients remains controversial. While several series have shown that surgical AVR in 
patients with severe AS with low gradient and preserved LVEF portends better prognosis 
compared with medical treatment,11, 14, 20-22 other studies have shown that the prognosis of 
these patients medically treated is similar to that of patients with moderate aortic stenosis.5, 
10 The study by Hachicha et al. including 512 patients with severe AS and preserved LVEF, 
62% of them with low gradient, showed that patients undergoing surgical AVR had better 
survival than patients treated medically.3 Similarly, Ozkan et al. confirmed that patients with 
symptomatic severe AS, low gradient and preserved LVEF had better prognosis compared 
to medically treated patients (26% versus 40% mortality after 28 months of mean follow-
up).11 In contrast, Jander et al. demonstrated that patients with asymptomatic severe AS, low 
gradient and preserved LVEF had comparable outcome to patients with moderate aortic 
stenosis (major cardiovascular events 14.8±1.0% versus 14.1±1.5%, respectively; p=0.59).5 
Accordingly, the authors considered that patients with low gradient, preserved LVEF severe 
AS do not represent a true severe AS group and the progression of the disease is similar to 
moderate aortic stenosis.5, 10 
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 These apparently conflicting results may be explained by differences within the group 
of patients with low gradient, preserved LVEF severe AS. Based on LV stroke volume, 
patients with preserved LVEF, low gradient severe AS can be further divided into low flow 
(≤35 ml/m2) or normal flow (>35ml/m2) and these two subgroups of patients have distinct 
clinical and echocardiographic characteristics: the former are more frequently female and 
older, have higher systemic vascular resistance, lower systemic compliance and higher LV 
global afterload than the normal flow patients.4, 6, 21 In addition, low flow patients show 
smaller LV outflow tract and LV cavity dimensions, increased concentric remodelling and 
lower LVEF (although within the normal range) than normal flow patients.4, 10 The increased 
concentric LV remodelling may have a significant impact on the LV mechanics that cannot 
be unmasked by LVEF alone. Two-dimensional speckle tracking longitudinal strain analysis 
can discriminate between these two groups of patients. Lancellotti et al showed that patients 
with preserved LVEF, low flow-low gradient severe AS had more impaired global longitudinal 
strain as compared with patients with normal flow-low gradient severe AS (-13.6±4.3% vs. -
16.7±2.6%, p<0.001).23 Therefore, low flow-low gradient severe AS may represent a more 
progressed disease status and the assessment of LV remodelling and global longitudinal 
strain may help distinguishing these two subgroups.  
While the prognostic implications of flow (SVi) in patients with low gradient severe AS 
and preserved LVEF remains debated, the impact of LV global longitudinal strain on the 
outcome of these patients has not been evaluated. In the sub-study of the Simvastatin and 
Ezetimibe in Aortic Stenosis trial (including 435 patients with asymptomatic low gradient 
severe AS) Jander et al.5 proposed that patients with low flow and patients with normal flow 
had comparable outcomes in terms of aortic valve and cardiovascular events and 
cardiovascular death. However, the outcome after AVR was not evaluated. In contrast, the 
studies by Hachicha et al.4 and Ozkan et al.11 suggested that survival after AVR is 
comparable between low flow and normal flow severe AS patients. Mehrotra et al.10 provided 
further evidence to the association between flow and survival in patients with low gradient 
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severe AS and suggested that patients with low flow severe AS had worse survival than 
normal flow severe AS and patients with moderate aortic stenosis. However, flow was not 
independently associated with survival of patients with low gradient severe AS. Similarly, 
Mohty et al.21 reported an independent association between flow and survival in patients with 
severe AS and after correcting for AVR (as time-dependent covariate), low flow-low gradient 
severe AS was associated with increased all-cause mortality risk (hazard ratio 1.84, 
p=0.014). The present study is in line with the results by Mohty et al.21 demonstrating that 
flow status is independently associated with long-term outcome of patients with low gradient 
severe AS and preserved LVEF treated with AVR. However, the present study provides also 
incremental value by demonstrating the independent association between LV global 
longitudinal strain and outcome in this group of patients. After correcting for SVi, LV global 
longitudinal strain was associated with all-cause mortality.  LV global longitudinal strain may 
be impaired in patients with low gradient severe AS and preserved LVEF possibly due to 
subendocardial ischemia, myocardial fibrosis, concentric remodelling or increased 
afterload.6, 16, 24 LV global longitudinal strain can detect the subtle intrinsic myocardial systolic 
dysfunction and its impairment precedes LVEF reduction.16, 25 However, randomized studies 
would be preferable to confirm the benefits of AVR in this subgroup of patients and impact 
on current practice guidelines.1 
Several limitations should be acknowledged. Outcome and echocardiographic data 
were retrospectively analysed. In addition, patients underwent surgical or transcatheter AVR, 
introducing a important prognostic bias. We did not use a propensity score to account for this 
difference. Finally, we did not include a comparator group who were medically treated. 
However, the comparison of prognostic implications of medical treatment vs. AVR in this 
group of patients was beyond the scope of the present evaluation.   
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FIGURE LEGENDS 
 
Figure 1. Patient population. AVAi, aortic valve area index; AVR, aortic valve replacement; 
LVEF, left ventricular ejection fraction; MPG, mean pressure gradient.   
 
Figure 2. Impact of flow on survival of patients with low gradient severe aortic stenosis and 
preserved ejection fraction after aortic valve replacement. After adjusting for age, atrial 
fibrillation, chronic obstructive pulmonary disease, chronic kidney disease, New York Heart 
Association functional class and left ventricular systolic function assessed by global 
longitudinal strain, normal flow (stroke volume index>35ml/m2) patients had better outcome 
than patients with low flow (stroke volume index≤35ml/m2). CI, confidence interval; HR, 
hazard ratio.  
 
Figure 3. Impact of left ventricular global longitudinal strain (GLS) on survival of patients with 
low gradient severe aortic stenosis and preserved ejection fraction after aortic valve 
replacement. After adjusting for age, atrial fibrillation, chronic obstructive pulmonary disease, 
chronic kidney disease, New York Heart Association functional class and flow expressed as 
stroke volume index, patients with better GLS (≤-15%) had better outcome than patients with 
GLS >-15%. CI, confidence interval; HR, hazard ratio. 
 
Figure 4. Impact of flow and left ventricular global longitudinal strain (GLS) on survival of 
patients with low gradient severe aortic stenosis and preserved ejection fraction after aortic 
valve replacement. Patients with low flow and more impaired GLS (>-15%) had significantly 
worse outcome compared with the other groups. 
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Table 1 
Baseline clinical characteristics 
Variable 
Overall 
(N=134) 
Survivors 
(N=108) 
Non-Survivors 
(N=26) 
p-value 
Age (years) 76 ± 10 75 ± 11 76 ± 5 0.24 
Male  67 (50%) 53 (49%) 14 (54%) 0.66 
Body mass index (Kg/m2) 26 ± 4 26 ± 4 26 ± 4 0.92 
Body surface area (m2) 1.9 ± 0.2 1.8 ± 0.2 1.9 ± 0.2 0.64 
Atrial fibrillation 10 (8%) 5 (5%) 5 (21%) 0.008 
Chronic kidney disease 28 (21%) 16 (15%) 12 (46%) 0.001 
Hypertension 98 (74%) 76 (71%) 22 (85%) 0.16 
Diabetes mellitus  34 (25%) 24 (22%) 10 (39%) 0.09 
Hyperlipidemia 69 (52%) 59 (56%) 10 (39%) 0.12 
Smoker 44 (34%) 35 (33%) 9 (36%) 0.77 
Family history of CAD 34 (27%) 28 (27%) 6 (24%) 0.75 
Coronary artery disease 83 (69%) 67 (69%) 16 (67%) 0.76 
Previous cardiac surgery 33 (25%) 22 (20%) 11 (42%) 0.02 
Myocardial infarction 19 (14%) 13 (12%) 6 (23%) 0.15 
Stroke 16 (12%) 11 (10%) 5 (20%) 0.17 
Chronic obstructive pulmonary 
disease 
35 (26%) 24 (22%) 11 (42%) 0.04 
Logistic EuroSCORE (%) 14 ± 12 13 ± 11 18 ± 13 0.08 
ACEi / ARB 66 (50%) 49 (46%) 17 (65%) 0.07 
Beta-blocker 77 (58%) 64 (60%) 13 (50%) 0.36 
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Calcium channel blocker 39 (30%) 28 (26%) 11 (42%) 0.12 
Statin 79 (59%) 64 (60%) 15 (58%) 0.84 
Diuretics 62 (47%) 47 (44%) 15 (58%) 0.21 
NYHA class I 40 (30%) 36 (33%) 4 (15%) 
0.04 
                    II 46 (34%) 37 (34%) 9 (35%) 
                    III 38 (28%) 30 (28%) 8 (31%) 
                    IV 10 (8%) 5 (5%) 5 (19%) 
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, 
coronary artery disease; NYHA, New York Heart Association.  
Hyperlipidemia, defined as serum total cholesterol ≥230 mg/dl and/or serum triglycerides 
≥200 mg/dl and/or treatment with lipid lowering drugs. Family history of CAD, defined as first 
degree relatives of <55 years in men and <65 years in women who had a cardiac event. 
Coronary artery disease, defined as previous coronary artery bypass grafting or 
percutaneous coronary intervention or more than 50% stenosis at the coronary angiography. 
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Table 2 
Baseline echocardiographic characteristics 
 Overall 
(N=134) 
Survivors 
(N=108) 
Non-Survivors 
(N=26) 
p-value 
Aortic valve area (cm2) 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.2 0.13 
Aortic valve area index (cm2/m2) 0.4 ± 0.1 0.5 ± 0.1 0.4 ± 0.1 0.12 
Peak velocity (m/s) 3.6 ± 0.4 3.6 ± 0.4 3.6 ± 0.4 0.74 
Mean gradient (mmHg) 32 ± 6 32 ± 6 32 ± 7 0.93 
Energy loss index (cm2/m2) 0.5 ± 0.1 0.5 ± 0.1 0.4 ±  0.1 0.09 
Valvulo-arterial impedance  (mmHg/ml/m2) 4.9 ± 1.5 4.7 ± 1.4 5.6 ± 1.5 0.004 
Systemic vascular resistance (mmHg.min/l) 1741 ± 504 1695 ± 500 1932 ± 485 0.03 
Systemic arterial compliance (ml/mmHg/m2) 0.6 ± 0.2 0.6 ± 0.2 0.6 ± 0.1 0.16 
Septal wall thickness in diastole (cm) 1.3 ± 0.2 1.3 ± 0.2 1.4 ± 0.3 0.11 
Posterior wall thickness in diastole (cm) 1.2 ± 0.2 1.2 ± 0.2 1.3 ± 0.2 0.08 
LVEDDi (cm/m2) 2.5 ± 0.3 2.5 ± 0.3 2.5 ± 0.3 0.69 
LVESDi (cm/m2) 1.5 ± 0.4 1.5 ± 0.3 1.5 ± 0.4 0.62 
Left ventricular mass index (g/m2) 121 ± 32 118 ± 32 131 ± 31 0.06 
Relative wall thickness (%) 56 ± 13 55 ± 13 58 ± 17 0.31 
LVEDVi (ml/m2) 49 ± 17 49 ± 17 47 ± 19 0.49 
LVESVi (ml/m2) 20 ± 8 20 ± 8 19 ± 8 0.85 
Left ventricular mass / LVEDV ratio (g/ml) 2.7 ± 1.2 2.6 ± 1.1 3.2 ± 1.3 0.03 
Ejection fraction (%) 61 ± 6 62 ± 6 59 ± 5 0.08 
Stroke volume index (ml/m2) 38 ± 10 39 ± 9 33 ± 10 0.001 
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Cardiac Output (l/min) 4.8 ± 1.1 4.9 ± 1.1 4.4 ± 0.9 0.03 
Cardiac Index (l/min/m2) 2.6 ± 0.6 2.6 ± 0.6 2.3 ± 0.5 0.02 
Stroke Work (g.m) 124 ± 35 127 ± 34 110 ± 16 0.02 
Stroke Work /100g (g.m) 60 ± 26 62 ± 25 48 ± 25 0.01 
Global longitudinal strain (%)  -15 ± 3 -15 ± 3 -13 ± 3 0.005 
E wave velocity (cm/s) 77 ± 28 76 ± 29 81 ± 25 0.39 
Deceleration time (msec) 257 ± 100 263 ± 98 232 ± 106 0.15 
Left atrial volume index (ml/m2) 37 ± 15 37 ± 16 37 ± 15 0.95 
Aortic regurgitation no/mild/moderate, n 56/66/12 42/54/12 14/12/0 0.13 
Mitral regurgitation no/mild/moderate, n 67/53/14 55/41/12 12/12/2 0.71 
LVEDDi, left ventricular end-diastolic diameter index; LVEDVi, left ventricular end-diastolic 
volume index; LVESDi, left ventricular end-systolic diameter index; LVESVi, left ventricular 
end-systolic volume index. 
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Table 3 
Univariate and multivariate Cox regression analysis to identify determinants of all-cause mortality in patients with low gradient, preserved 
ejection fraction severe aortic stenosis after aortic valve replacement 
 Univariate Analysis Multivariate Analysis 
 HR 95% CI p-value HR 95% CI p-value 
Clinical Variables       
       Age (years) 1.04 0.99-1.09 0.08 1.01 0.93-1.09 0.78 
       Male gender 1.49 0.68-3.29 0.32    
       Body mass index (Kg/m2) 1.01 0.91-1.13 0.81    
       Transcatheter aortic valve replacement 1.69 0.74-3.89 0.21    
       Logistic EuroScore (%) 1.03 1.00-1.06 0.03 0.98 0.92-1.06 0.69 
       Coronary artery disease 0.96 0.40-2.27 0.92    
       Chronic kidney disease 2.60 1.18-5.74 0.02 3.20 1.10-9.31 0.03 
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       Atrial fibrillation 3.45 1.26-9.40 0.02 4.63 1.22-17.62 0.02 
       Hypertension 2.28 0.78-6.69 0.13    
       Diabetes  1.64 0.72-3.71 0.24    
       Hyperlipidemia 0.63 0.28-1.43 0.23    
       Previous cardiac surgery 2.37 1.06-5.29 0.04 0.97 0.20-4.71 0.97 
       Myocardial infarction 2.96 1.16-7.55 0.02 2.57 0.55-12.04 0.23 
       Stroke 2.08 0.76-5.65 0.15    
       Chronic obstructive pulmonary disease 2.57 1.15-5.77 0.02 1.45 0.49-4.25 0.50 
       New York Heart Association, class I Ref  0.08   0.62 
                                                               II 3.20 0.96-10.47 0.06 1.75 0.45-6.80 0.42 
                                                               III 2.72 0.77-9.27 0.10 2.07 0.51-8.33 0.31 
                                                               IV 5.63 1.49-21.15 0.01 2.82 0.55-14.26 0.21 
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Echocardiographic Variables       
       Aortic valve area index (cm2/m2) 0.06 0.001-5.18 0.21    
       Mean pressure gradient (mmHg) 0.98 0.93-1.05 0.61    
       Valvulo-arterial impedance (mmHg/ml/m2) 1.26 1.02-1.57 0.03 1.08 0.80-1.49 0.66 
       Left ventricular mass index (g/m2) 1.01 0.99-1.02 0.23    
       Relative wall thickness (%) 1.02 0.99-1.05 0.12    
       Left ventricular mass / LVEDV ratio (g/ml)  1.63 1.27-2.10 0.001 1.44 0.95-2.17 0.08 
       Left ventricular ejection fraction (%) 0.94 0.87-1.00 0.07 0.97 0.89-1.06 0.56 
       Left atrium volume index (ml/m2) 0.99 0.97-1.02 0.71    
CI, confidence interval; HR, hazard ratio; LVEDV, left ventricular end-diastolic volume. 
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Table 4 
Multivariate Cox regression analysis and c-statistics to test the value of flow (stroke volume index category > and ≤35ml/m2 or increase per 
5ml/m2) and left ventricular systolic function (global longitudinal strain category > and ≤-15% or increase per +1%) on baseline model (please 
look at table 3) predicting mortality in low gradient, preserved ejection fraction severe aortic stenosis after aortic valve replacement 
 Multivariate Analysis Model Comparison 
 HR 95% CI p-value* Model -2Log Likelihood Model x2 p-value† C-statistics 
Baseline model 173.34 14.52 - 0.68 
      Atrial fibrillation 5.40 1.81-16.07 0.002     
      Chronic kidney disease 3.67 1.49-9.06 0.005     
Baseline model + GLS category 166.80 19.87 0.029 0.74 
      Atrial fibrillation 4.03 1.33-12.18 0.014     
      Chronic kidney disease 3.95 1.61-9.69 0.003     
      Global longitudinal strain ≤-15% 0.37 0.14-0.94 0.036     
Baseline model + SVi category 158.06 29.62 <0.001 0.80 
      Atrial fibrillation 3.18 1.00-10.07 0.050     
      Chronic kidney disease 3.59 1.41-9.11 0.007     
      Stroke volume index >35ml/m2 0.16 0.06-0.44 <0.001     
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Baseline model + GLS 1% increase 164.09 22.29 0.006 0.78 
      Atrial fibrillation 3.49 1.11-10.92 0.03     
      Chronic kidney disease 3.74 1.50-9.31 0.005     
      Global longitudinal strain  1.21 1.05-1.39 0.007     
Baseline model + SVi 5ml/m2 increase 167.86 19.77 0.019 0.77 
      Atrial fibrillation 3.16 0.93-10.45 0.07     
      Chronic kidney disease 3.57 1.44-8.99 0.006     
      Stroke volume index  0.77 0.61-0.97 0.03     
*p-value by multivariate Cox regression analysis 
†p-value by likelihood ratio test vs. baseline model 
CI, confidence interval; GLS, Global longitudinal strain; HR, hazard ratio; SVi, Stroke volume index.   
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Highlights 
• Survival of low-gradient severe AS patients with preserved LVEF was evaluated. 
• The prognostic association of flow and LV global longitudinal strain was assessed. 
• Global longitudinal strain and flow were independently associated with survival after 
aortic valve replacement. 
 
